DiaMedica Therapeutics Inc. Profile Avatar - Palmy Investing

DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX tria…

Biotechnology
US, Minneapolis [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group

Peers Performance

A quick analysis that compared DiaMedica Therapeutics Inc. (DMAC) to it's peer group.

Peer Group
LIFE XFOR DAWN HOOK GRTX SCPH TERN IKT LYRA MCRB IOVA Compare Together
Loading...
End of DMAC's Analysis
CIK: 1401040 CUSIP: 25253X207 ISIN: CA25253X2077 LEI: - UEI: -
Secondary Listings
DMAC has no secondary listings inside our databases.